Abstract 1937P
Background
To clarify the clinicopathological features and clinical outcomes of histological subtypes of papillary thyroid carcinoma (PTC) in the pediatric and adolescent population treated at a single institution.
Methods
A total of 153 PTC patients ≤18 years of age who underwent initial surgery between 1979 and 2019 were investigated. The most common subtypes included classic PTC in 124 (81%), solid variant in 16 (10%), diffuse sclerosing variant in 7 (5%), and follicular variant in 6 (4%). Cause-specific survival (CSS) and disease-free survival (DFS) rates were calculated by the Kaplan–Meier method.
Results
There were 135 female and 18 male patients, with a mean age at the time of surgery of 16 (range, 8-18) years, and 5% (8 patients) were ≤10 years of age at diagnosis. At initial surgery, 49 patients (32%) had lymph node metastases diagnosed preoperatively (cN1), 16 (10%) had gross extrathyroidal extension (ETE), and 18 (12%) had lung metastases. Total thyroidectomy was performed in 55 (36%) patients, and 98 (64%) patients underwent less than total thyroidectomy. During a mean follow-up of 16 years, 3 patients died of their disease, and 34 patients had recurrent disease. The 30-year CSS rate was 97.2%, and the 30-year DFS rate was 65.0%. On univariate analysis, extensive ETE (p=0.001) and cN1 (p=0.003), but not histological subtype (p=0.21), were associated with disease recurrence. Extensive ETE and cN1 were identified as significant factors related to DFS on multivariate analysis (hazard ratio (HR) 5.2, confidence interval (CI) 1.9-12.4, p=0.0028; HR 3.2, CI.6-6.6, p=0.0021).
Conclusions
The prognosis of pediatric patients with PTC was good, but recurrence was common. In pediatric PTC, histological subtype did not affect survival and recurrence.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Presenter: Lai-Man Mok
Session: Poster session 18
1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Presenter: Minggui Pan
Session: Poster session 18
1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Presenter: Marcia Cruz-Correa
Session: Poster session 18
1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Presenter: Yoon-Koo Kang
Session: Poster session 18
1439P - ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Presenter: John Strickler
Session: Poster session 18
1440P - Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial
Presenter: Chao Cheng
Session: Poster session 18
1441P - Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer
Presenter: Weiyao Li
Session: Poster session 18
1442P - Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
Presenter: Hiroki Osumi
Session: Poster session 18
1444P - Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-Americans
Presenter: Shubham Gulati
Session: Poster session 18